Commercial Hims & Hers expects to establish a weight reduction...

Hims & Hers expects to establish a weight reduction company by year-end


Hims & Hers, a company specializing in online health and wellness products, announced its strategic entry into the thriving weight loss market. This move marks a departure from its previous focus and indicates a commitment to diversification and expansion.

In comparison to its industry counterparts, Hims & Hers took a deliberate approach to entering the weight management arena. The company’s CEO and co-founder, Andrew Dudum, stated that the development of their weight management solutions had been in progress for over a year. Dudum highlighted the intention to leverage the company’s strengths, emphasizing personalized treatments that cater to the specific clinical needs of their customers.

The forthcoming weight management offerings are designed to be cost-effective and will encompass a blend of established prescription medications and nutritional guidance. Although Hims & Hers is engineering these products to accommodate current and future medications, it’s noted that supply chain uncertainties might delay the inclusion of certain elements initially.

Dudum explained that the initial range of options would likely consist of generic alternatives targeting root causes of weight gain, such as metabolic resistance, hormonal imbalances, and mental health factors like depression. This strategic approach underscores the company’s commitment to addressing a variety of weight-related concerns comprehensively.

In the second quarter of 2023, Hims & Hers generated substantial revenue amounting to $208 million, up from $113 million the previous year. The online segment of their business also witnessed significant growth, with online revenue surging by 87% year over year, reaching $201 million in the second quarter. This was attributed to a surge in subscribers, which expanded by 74% compared to the previous year, totaling 1.3 million subscribers.

The company’s financial performance was equally impressive, as it managed to narrow its losses during the same period. A year-on-year comparison reveals that losses decreased from $19.7 million to $7.2 million, reflecting a commendable financial turnaround.

Furthermore, the company celebrated its achievement of another EBITDA-adjusted profitable quarter, amassing $10.6 million compared to a loss of $7.5 million in the corresponding period of the previous year.

In collaboration with Labcorp, Hims & Hers introduced lab-based heart health testing, with results seamlessly integrated into their proprietary electronic medical record system. This integration empowers healthcare providers to further personalize care based on patients’ test results.

Hims & Hers is also investing in the advancement of its analytics and artificial intelligence capabilities, aiming to leverage data for precision treatments. An AI tool named MedMatch is in development, designed to predict diagnoses and recommend appropriate treatments, aiding healthcare providers in making well-informed and clinically relevant decisions.

The company’s growth trajectory has enabled it to reduce prices for certain products and services, fostering increased accessibility to personalized subscriptions. Over 20% of total subscribers at the end of the second quarter were already benefiting from personalized solutions, indicating a strong demand for tailored treatment plans.

+ posts

Latest news

Revvity introduces advanced preclinical imaging tech for scientists to make breakthroughs

Revvity, Inc. is ushering in a new era of innovation in the realm of preclinical research by...

European Commission Approves Updated Pfizer-BioNTech Vaccine for Omicron XBB.1.5 Variant

The European Commission has recently achieved a significant milestone in the ongoing battle against COVID-19 in preparation...

NICE gives Chiesi’s Elfabrio go ahead

Chiesi has recently garnered a favorable recommendation from the National Institute for Health and Care Excellence (NICE)...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you